| 5.728 -0.332 (-5.48%) | 09-16 11:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.19 | 1-year : | 9.57 |
| Resists | First : | 7.01 | Second : | 8.19 |
| Pivot price | 3.55  |
|||
| Supports | First : | 2.86 | Second : | 0.3 |
| MAs | MA(5) : | 6.13 |
MA(20) : | 2.75 |
| MA(100) : | 0.9 |
MA(250) : | 0.79 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 84.4 |
D(3) : | 87 |
| RSI | RSI(14): 78.5 |
|||
| 52-week | High : | 7.01 | Low : | 0.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CTSO ] has closed below upper band by 31.5%. Bollinger Bands are 1165.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.2 - 6.24 | 6.24 - 6.28 |
| Low: | 5.9 - 5.94 | 5.94 - 5.97 |
| Close: | 6 - 6.07 | 6.07 - 6.12 |
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Mon, 14 Sep 2026
CTSO: Blood purification sales grow globally as DrugSorb-ATR nears FDA submission with strong clinical data - TradingView
Sat, 12 Sep 2026
Return on assets % of CytoSorbents Corporation – BX:CTSO - TradingView
Thu, 10 Sep 2026
Blood-purification company CytoSorbents heads to New York for a Sept. 14 talk - Stock Titan
Wed, 09 Sep 2026
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com
Wed, 09 Sep 2026
Cytosorbents Corp (CTSO) CEO bought more shares in the open market, adding to his stake - Stock Titan
Thu, 03 Sep 2026
CytoSorbents Announces Reverse Stock Split - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 63 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 15.6 (%) |
| Held by Institutions | 27 (%) |
| Shares Short | 2,040 (K) |
| Shares Short P.Month | 1,990 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | -27.8 % |
| Operating Margin | -28.1 % |
| Return on Assets (ttm) | -19.1 % |
| Return on Equity (ttm) | -93.3 % |
| Qtrly Rev. Growth | 10.1 % |
| Gross Profit (p.s.) | 0.41 |
| Sales Per Share | 0.58 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -32.11 |
| PEG Ratio | 0 |
| Price to Book value | 41.28 |
| Price to Sales | 9.81 |
| Price to Cash Flow | -36.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|